… While management of patients’ immune-related adverse effects is outside the scope of this
… about the potential adverse effects of immunotherapies as well as referrals, as necessary. …

… the management and treatment of human lung cancer (56… lung cancer will provide the basis
for the design of allosteric α5-nAChR ligands with improved biological activity and side effect …

… We retrospectively screened patients with pathologically confirmed advanced or recurrent
non-small cell lung cancer (NSCLC) who had received PD-1/PD-L1 inhibitors at Kurume …

… , balance the benefits and harms, and proceed with treatment as a shared decision with
individuals willing to take on additional adverse effects and risk. For example, meta-analyses …

… of the patients with a response were continuing treatment or had undergone curative-intent
surgery. The side effects were mostly gastrointestinal side effects, but approximately 30% of …

… Anti–programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune
… for non–small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs) …

… of the T cell repertoire in localized lung cancers, we performed next … tumors from
treatment-naïve NSCLC patients 16,17 . T … -tumor-specific background mutations may be …

… into small cell lung cancer (SCLC) and non-small cell lung cancer (… 85% of all lung cancers
with poor curative effect [3,4]. The … cell proliferation of anaplastic lymphoma kinase-negative …

… have a substantial negative effect on outcomes with … to treatment-related toxicity, and also
a more traditional definition that includes the incidence of treatment-related grade 3–5 adverse …

… The adverse events of the combination treatment were tolerable in our patients, so the
combination was safe and could be popularized in the future. The most common grade 1-2 …